Literature DB >> 27578110

Effects of DHA-enriched fish oil on monocyte/macrophage activation marker sCD163, asymmetric dimethyl arginine, and insulin resistance in type 2 diabetic patients.

Omid Toupchian1, Gity Sotoudeh2, Anahita Mansoori3, Ensieh Nasli-Esfahani4, Mahmoud Djalali1, Seyyed Ali Keshavarz5, Fariba Koohdani6.   

Abstract

BACKGROUND: The beneficial effects of n-3 polyunsaturated fatty acids on reducing cardiovascular risks are well documented. However, the relative effect on some markers of macrophage activation and vascular function is unclear.
OBJECTIVE: The primary objective of this study was to investigate the effects of docosahexaenoic acid (DHA)-enriched fish oil on the marker of monocyte/macrophage activation factor soluble CD163, asymmetric dimethyl arginine (ADMA), and insulin resistance in type 2 diabetic patients.
METHODS: In this double-blind randomized controlled trial, 72 type 2 diabetic patients with an age between 30-70 years and body mass index (BMI) of 18.5 to 40 kg/m(2) were randomly assigned to receive 2.4-g DHA-enriched fish oil or placebo per day for 8 weeks. Anthropometric measurements, biochemical, and body composition analyses were assessed at baseline and end of study. Analysis of covariance (ANCOVA) was conducted by controlling for possible confounders to assess between-group differences.
RESULTS: Serum levels of sCD163, triglycerides, waist circumference (WC), and weight to height ratio (WHtR) decreased significantly in the fish oil group when compared with the control group. Serum ADMA concentration decreased in the fish oil group with no significant between-group differences. Controlling for confounders revealed that the differences observed in sCD163, triglycerides, WC, and WHtR remained statistically significant.
CONCLUSIONS: Short-time fish oil supplementation decreased serum sCD163, triglycerides levels, WC, and WHtR in T2DM patients. Because of the positive relationship between sCD163 levels and some T2DM and obesity-related complications, it seems that DHA can be considered as a key intervention in obesity and T2DM.
Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asymmetric dimethyl arginine; Body mass index; Docosahexaenoic acid; Insulin resistance; Type 2 diabetes; sCD163

Mesh:

Substances:

Year:  2016        PMID: 27578110     DOI: 10.1016/j.jacl.2016.02.013

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

1.  The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial.

Authors:  Shima Abdollahi; Amin Salehi-Abargouei; Mahtab Tabatabaie; Mohammad Hasan Sheikhha; Hossein Fallahzadeh; Masoud Rahmanian; Omid Toupchian; Elham Karimi-Nazari; Hassan Mozaffari-Khosravi
Journal:  BMJ Open       Date:  2019-07-04       Impact factor: 2.692

Review 2.  Bioactive Compounds for the Management of Hypertriglyceridemia: Evidence From Clinical Trials and Putative Action Targets.

Authors:  Elisabetta Schiano; Giuseppe Annunziata; Roberto Ciampaglia; Fortuna Iannuzzo; Maria Maisto; Gian Carlo Tenore; Ettore Novellino
Journal:  Front Nutr       Date:  2020-11-30

3.  The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes.

Authors:  Reina Kawarabayashi; Koka Motoyama; Miyuki Nakamura; Yuko Yamazaki; Tomoaki Morioka; Katsuhito Mori; Shinya Fukumoto; Yasuo Imanishi; Atsushi Shioi; Tetsuo Shoji; Masanori Emoto; Masaaki Inaba
Journal:  J Diabetes Res       Date:  2017-12-28       Impact factor: 4.011

Review 4.  Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis.

Authors:  Huanqing Gao; Tingting Geng; Tao Huang; Qinghua Zhao
Journal:  Lipids Health Dis       Date:  2017-07-03       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.